A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The phase I/II study was designed to evaluate if the regimen of Irinotecan, Oxaliplatin,
Capecitabine (XELOXIRI) and Bevacizumab is a superior first-line option for patients with
metastatic colorectal cancer(mCRC) in terms of safety and efficacy.